内容紹介
Assessment of the Vulnerable Elders Survey as a Predictive Test for Elderly Patients with Advanced or Metastatic Gastric Cancer Treated with Combined S-1 and Docetaxel Therapy
Summary
Ten patients aged 75 years or more with advanced or metastatic gastric cancer were prescribed S-1 plus docetaxel(DOC)combination therapy. None of the patients showed complete response, but 2 showed partial response and 4 showed stable disease. Grade 3 or 4 toxicities occurred in 3 patients. Three patients with performance status(PS)1 achieved partial response or stable disease and were free of Grade 3 or 4 toxicities, whereas the response and occurrence of adverse events in 7 patients with PS 2 varied widely. In these patients, an investigation of the relationship between response to treatment and the Vulnerable Elders Survey(VES-13)score showed that VES-13 scores were higher in the non-response group than in the other patients and in patients who experienced adverse events than in those who did not. These findings suggest that VES-13 could be a useful screening tool for predicting response and the occurrence of adverse events in elderly patients undergoing combined S-1 plus DOC therapy for advanced or metastatic gastric cancer.
要旨
後期高齢者切除不能・進行再発胃癌患者に対するS-1+DOC療法を10例の患者に対して施行した結果,奏効率20%,部分奏効2例,安定4例で,Grade 3以上の有害事象は3例に認められた。performance status(PS)1であった3例ではいずれも病勢阻止が得られ,Grade 3以上の副作用も認められなかったが,PS 2であった7例では治療効果,有害事象の発現に個人差がみられた。PS 2であった症例において高齢者脆弱性評価ツールであるVulnerable Elders Survey(VES-13)で治療効果と有害事象発現の関係を検討してみると,治療効果不良群,有害事象発現群でVES-13が高い傾向がみられた。後期高齢者切除不能・進行再発胃癌に対するS-1+DOC療法を施行する際にVES-13は治療効果,有害事象発現のスクリーニングツールとして有用である可能性が示唆された。
目次
Summary
Ten patients aged 75 years or more with advanced or metastatic gastric cancer were prescribed S-1 plus docetaxel(DOC)combination therapy. None of the patients showed complete response, but 2 showed partial response and 4 showed stable disease. Grade 3 or 4 toxicities occurred in 3 patients. Three patients with performance status(PS)1 achieved partial response or stable disease and were free of Grade 3 or 4 toxicities, whereas the response and occurrence of adverse events in 7 patients with PS 2 varied widely. In these patients, an investigation of the relationship between response to treatment and the Vulnerable Elders Survey(VES-13)score showed that VES-13 scores were higher in the non-response group than in the other patients and in patients who experienced adverse events than in those who did not. These findings suggest that VES-13 could be a useful screening tool for predicting response and the occurrence of adverse events in elderly patients undergoing combined S-1 plus DOC therapy for advanced or metastatic gastric cancer.
要旨
後期高齢者切除不能・進行再発胃癌患者に対するS-1+DOC療法を10例の患者に対して施行した結果,奏効率20%,部分奏効2例,安定4例で,Grade 3以上の有害事象は3例に認められた。performance status(PS)1であった3例ではいずれも病勢阻止が得られ,Grade 3以上の副作用も認められなかったが,PS 2であった7例では治療効果,有害事象の発現に個人差がみられた。PS 2であった症例において高齢者脆弱性評価ツールであるVulnerable Elders Survey(VES-13)で治療効果と有害事象発現の関係を検討してみると,治療効果不良群,有害事象発現群でVES-13が高い傾向がみられた。後期高齢者切除不能・進行再発胃癌に対するS-1+DOC療法を施行する際にVES-13は治療効果,有害事象発現のスクリーニングツールとして有用である可能性が示唆された。